Mahdi Zeraati
Cancer Institute Fellow University of Sydney
I am a biomedical researcher focused on translating cutting-edge scientific discoveries into commercial ventures. My expertise includes developing antibodies against challenging targets, such as the globally distributed i-Motif-specific antibody (iMab), which is widely used in high-impact studies. As a Cancer Institute NSW Early Career Fellow, I lead projects advancing novel antibody therapies and mRNA technology for potential cancer treatments. Passionate about bridging the gap between academia and industry, I leverage both my research expertise and newly acquired business acumen from a mini-MBA to strategically pursue commercialisation opportunities with a focus on real-world impact and innovation.
Seminars
- Evaluate how LNP design choices impact therapeutic performance in real disease models
- Identify gaps between delivery optimisation and clinical application needs
- Assess how researchers adapt existing LNP platforms for specific therapeutic use cases
- Highlight where current LNP systems fall short from an end-user perspective
